Research Paper Volume 16, Issue 4 pp 3716—3733

miR-557 inhibits hepatocellular carcinoma progression through Wnt/β-catenin signaling pathway by targeting RAB10

class="figure-viewer-img"

Figure 5. MiR-557 targets RAB10 to affect the process of EMT and inhibit Wnt/β-catenin signaling. (A) The protein of EMT process of NC cells, miR-557-overexpression cells, RAB10-overexpression cells, co-transfected miR-557 mimics and pmirGLO-RAB10 cells of MHCC-97H. (B) The protein of EMT process of NC cells, miR-557-down-expression cells, RAB10-down-expression cells, co-transfected miR-557 inhibitors and siRAB10 cells of Huh7. (C) GSEA of RAB10 expression and Wnt/β-catenin signaling. (D, E) TOP-flash/FOP-flash assays of mimic-NC cells and miR-557-overexpression cells of MHCC-97H, and TOP-flash/FOP-flash assays of inhibitor-NC cells and miR-557-inhibition cells of Huh7 cells. (F) Western blot analysis of AKT/FOXO3a signaling-related proteins in NC cells, miR-557-overexpression cells, RAB10-overexpression cells, co-transfected miR-557 mimics and pmirGLO-RAB10 cells of MHCC-97H. (G) Western blot analysis of AKT/FOXO3a signaling-related proteins in NC cells, miR-557-down-expression cells, RAB10-down-expression cells, co-transfected miR-557 inhibitors and siRAB10 cells of Huh7. All blots were cut prior to hybridisation with antibodies during western blotting. (****P<0.0001).